Filing Details
- Accession Number:
- 0001123292-16-003077
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-12-19 16:28:07
- Reporting Period:
- 2016-12-15
- Filing Date:
- 2016-12-19
- Accepted Time:
- 2016-12-19 16:28:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1588972 | Recro Pharma Inc. | REPH | Pharmaceutical Preparations (2834) | 261523233 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1602327 | Wayne Weisman | C/O Recro Pharma, Inc. 490 Lapp Road Malvern PA 19355 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-12-15 | 4,000 | $6.53 | 4,000 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2016-12-16 | 3,000 | $6.57 | 7,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.55, inclusive. The reporting person undertakes to provide to Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.55 to $6.61, inclusive. The reporting person undertakes to provide to Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.